<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00402194</url>
  </required_header>
  <id_info>
    <org_study_id>IU-IRB-0301-08</org_study_id>
    <nct_id>NCT00402194</nct_id>
  </id_info>
  <brief_title>Treating the Endothelium to Restore Insulin Sensitivity</brief_title>
  <official_title>Treating the Endothelium to Restore Insulin Sensitivity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study of 12 weeks' treatment with losartan or placebo, to test the hypothesis that RAS
      inhibition will improve insulin' vascular actions and therefore improve insulin sensitivity
      in skeletal muscle.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent studies suggesting an effect of cardiovascular therapies to prevent diabetes remain
      unexplained. We hypothesize that these therapies improve vascular endothelial function
      allowing improved actions of insulin in the vasculature, which comprise a significant portion
      of insulin's metabolic action. We therefore propose to measure insulin-mediated glucose
      disposal and insulin-mediated vasodilation before and after 12 weeks' therapy with Losartan
      (an angiotensin receptor blocker) or placebo, in a randomized design. Subjects will include
      28 subjects with impaired glucose tolerance, which is generally accompanied by both insulin
      resistance and impaired vascular function. With this number of participants we have a 90%
      chance of showing a statistically significant and clinically meaningful effect of insulin on
      leg vascular resistance, and an even higher chance of showing a difference in insulin's
      metabolic effects. Exclusion criteria will include frank hypertension, diabetes, or
      hypercholesterolemia, and biochemical or other contraindications to losartan therapy. The
      primary endpoint for statistical analysis will be the invasive measure of insulin-stimulated
      endothelial function. We anticipate an improvement in both vascular and metabolic measures of
      insulin action following Losartan therapy but no change from untreated baseline following
      placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Leg Blood Flow Response to Insulin</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin-stimulated Leg Glucose Uptake</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <enrollment type="Actual">17</enrollment>
  <condition>Obesity</condition>
  <condition>Insulin Resistance</condition>
  <condition>Impaired Glucose Tolerance</condition>
  <condition>Pre-diabetes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>Tablet, 100mg, once per day for 3 months</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy

          -  Age 20-55

          -  Male and female

          -  Obese, defined as Males: BMI &gt;28 or &gt; 30% fat by DEXA scan or Bod Pod; Females: BMI
             &gt;30 or &gt; 33% fat by DEXA scan or Bod Pod

          -  Weight stable over at least 4 months

        Exclusion Criteria:

          -  Diabetes mellitus (ADA criteria)

          -  Age &lt;20 or &gt; 55 yrs

          -  Blood pressure &gt;160/90 or &lt; 90/65 mmHg

          -  Total cholesterol &gt;240 or LDL cholesterol &gt;160 mg/dL

          -  Baseline elevations in AST or ALT &gt; 3X ULN

          -  Baseline elevation in creatinine &gt;1.6 ng/mL

          -  Unexplained baseline elevation in creatine kinase &gt; 3X ULN

          -  Concurrent significant chronic medical illness including, but not limited to, human
             immunodeficiency virus infection, Syphilis, hepatitis B infection, or hepatitis C
             infection

          -  Pregnancy

          -  Known hypersensitivity or intolerance to the study agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kieren J Mather, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University Hospital GCRC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2006</study_first_submitted>
  <study_first_submitted_qc>November 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2006</study_first_posted>
  <results_first_submitted>May 6, 2013</results_first_submitted>
  <results_first_submitted_qc>September 20, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 24, 2013</results_first_posted>
  <last_update_submitted>September 20, 2013</last_update_submitted>
  <last_update_submitted_qc>September 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Impaired glucose tolerance</keyword>
  <keyword>pre-diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited by word of mouth and flyers posted in key locations on campus.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>Treatment with 100mg of losartan daily. Outcomes measured before and after 3 months of treatment.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Treatment with double blinded placebo daily. Outcomes measured before and after 3 months of treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>Treatment with 100mg of losartan daily or placebo. Outcomes measured before and after 3 months of treatment.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.0" spread="8.7"/>
                    <measurement group_id="B2" value="36.5" spread="10.1"/>
                    <measurement group_id="B3" value="38.8" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Leg Blood Flow Response to Insulin</title>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Treatment with 100mg of losartan daily. Outcomes measured before and after 3 months of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Treatment with double blinded placebo daily. Outcomes measured before and after 3 months of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Leg Blood Flow Response to Insulin</title>
          <units>Liters/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Leg Blood Flow</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.05"/>
                    <measurement group_id="O2" value="0.26" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insulin stimulated leg blood flow</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.353" spread="0.327"/>
                    <measurement group_id="O2" value="0.046" spread="0.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Insulin-stimulated Leg Glucose Uptake</title>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Treatment with 100mg of losartan daily. Outcomes measured before and after 3 months of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Treatment with double blinded placebo daily. Outcomes measured before and after 3 months of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin-stimulated Leg Glucose Uptake</title>
          <units>mmol/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="0.08"/>
                    <measurement group_id="O2" value="0.30" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>Treatment with 100mg of losartan daily. Outcomes measured before and after 3 months of treatment.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Treatment with double blinded placebo daily. Outcomes measured before and after 3 months of treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Kieren Mather</name_or_title>
      <organization>Indiana University</organization>
      <phone>317-278-7826</phone>
      <email>kmather@iu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

